DIRS.INFO The most relevant business & tech news

☆ Philips CEO on $1.1 billion settlement over DreamStation sleep apnea machines
▼ + stars: | 2024-04-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPhilips CEO on $1.1 billion settlement over DreamStation sleep apnea machinesRoy Jakobs, Philips CEO, joins 'Money Movers' to discuss the company's recent settlement, the sales of the company's sleep apnea machines, and more.

Persons: Roy Jakobs Organizations: Philips

☆ Philips shares rocket 33% as firm settles U.S. respiratory device case
▼ + stars: | 2024-04-29 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Philips shares were 33% higher at 9:00 a.m. London time. It said it did not admit any fault or liability, or that any injuries were caused by its Respironics devices. Monday's rebound took Philips shares back to their highest level since April 2022. Adjusted earnings, meanwhile, beat consensus analyst expectations, according to Reuters, coming in at 388 million euros for the quarter. Sales were slightly lower year-on-year, at 4.14 billion euros in the first quarter from 4.17 billion euros in 2023.

Persons: Roy Jakobs, Philips Organizations: Philips, Reuters Locations: U.S, London

☆ 'Vast majority' of legal cases linked to sleep apnea devices recall now settled, Philips CEO says
▼ + stars: | 2024-04-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'Vast majority' of legal cases linked to sleep apnea devices recall now settled, Philips CEO saysPhilips CEO Roy Jakobs comments on the company's first-quarter results and its agreement of a $1.1 billion settlement for personal injury and medical monitoring claims linked to the recall of some respiratory devices.

Persons: Roy Jakobs Organizations: Philips

☆ Goldman names 3 'attractive' value stocks that offer more than 50% upside
▼ + stars: | 2024-02-13 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Goldman Sachs has identified three "attractive" value stocks that could see significant share price appreciation over the next 12 months. The Wall Street bank's analysts see over 50% upside potential in British Airways parent International Consolidated Airlines Group , agricultural machinery maker CNH Industrial , and health technology company Philips . Goldman Sachs said all three companies stand out amongst their European peers for their cheap valuations compared to earnings growth prospects. IAG-GB 1Y line Philips Goldman recommends buying Philips and expects the shares to be up 51% over the next 12 months. CNH Industrials Goldman Sachs upgraded CNH to buy last month.

Persons: Goldman Sachs, John Sawtell, Goldman's, Patrick Creuset, Creuset, Philips Goldman, Roy Jakobs, CNH Industrials Goldman Sachs, Michael Bloom Organizations: British Airways parent International Consolidated Airlines Group, Philips, CNBC Locations: Europe, United States

☆ Philips CEO on product recalls and deal with FDA
▼ + stars: | 2024-01-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPhilips CEO on product recalls and deal with FDARoy Jakobs, Philips CEO, joins 'Money Movers' to discuss how long the company will resume selling sleep apnea machines in the U.S., the safety of the company's devices, and more.

Persons: FDA Roy Jakobs Organizations: Philips, FDA Locations: U.S

WASHINGTON (AP) — The company behind a global recall of sleep apnea machines said Monday it will stop selling the devices in the U.S., under a tentative agreement with regulators that could cost the company nearly $400 million. Philips executives disclosed the tentative agreement during a quarterly earnings update. Under terms of the agreement, Philips would continue servicing recalled machines in the U.S., but would not be able to sell new ones until meeting several corrective actions laid out by the FDA. In November, the agency issued a new warning that the machines can overheat, in rare cases causing fires. Untreated sleep apnea can cause people to stop breathing hundreds of times per night, leading to dangerous drowsiness and increased heart attack risk.

Persons: ” Philips, Roy Jakobs, Philips, “, ” Organizations: WASHINGTON, Manufacturing, Philips, Food and Drug Administration, Department of Justice, FDA . Company, FDA, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Pennsylvania, Canada, Australia, Israel, Chile

☆ Philips reaches compliance agreement with FDA over ventilator recall
▼ + stars: | 2024-01-29 | by ( ) www.cnbc.com time to read: +1 min

Dutch health technology company Philips said on Monday it had reached an agreement on the terms of a settlement with the U.S. Food and Drug Administration (FDA) over a large-scale recall of ventilators. Philips said the costs of the so-called consent decree with the FDA led to a provision of 363 million euros ($393.5 million) in the fourth quarter of last year, and were expected to be about 1% of total revenues in 2024. The agreement sets out the improvements that Philips needs to make at its Respironics plants in order to be able to sell new respiratory devices in the U.S. again. Until the conditions are met, no new Respironics devices will be sold there, the company said. "We are fully committed to complying with the consent decree, which is an important step and provides a clear path forward," Chief Executive Roy Jakobs said in a statement.

Persons: Philips, Roy Jakobs Organizations: U.S . Food, Drug Administration, FDA, Philips Locations: Europe, U.S

☆ Philips CEO says company is 'pulling growth out of every single market' in the world
▼ + stars: | 2024-01-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPhilips CEO says company is 'pulling growth out of every single market' in the worldRoy Jakobs, CEO of Philips, discusses the company's earnings results as it strives to push through the brand's ventilator issues and DOJ investigations.

Persons: Roy Jakobs Organizations: Philips

☆ Technology is key in rebuilding Ukraine, Philips CEO says
▼ + stars: | 2024-01-17 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTechnology is key in rebuilding Ukraine, Philips CEO saysRoy Jakobs, the CEO of Philips, discusses the company's operations in Ukraine, and explains the applications of AI in the health care sector.

Persons: Roy Jakobs Organizations: Technology, Philips Locations: Ukraine

☆ Philips investor Exor: company's problems are "solvable"
▼ + stars: | 2023-11-30 | by ( Giulio Piovaccari | ) www.reuters.com time to read: +2 min

TURIN/AMSTERDAM, Nov 30 (Reuters) - The CEO of Exor NV (EXOR.AS), the largest shareholder in Dutch healthcare equipment maker Philips NV (PHG.AS), on Thursday said he continues to believe the company's problems are solvable. Exor owns a 15% stake in Philips. The recall wiped nearly two-thirds off Philips' stock market valuation and new CEO Roy Jakobs has said that resolving the issue is his top priority. Philips stock is currently trading at 18.77 euros, about 25 cents higher than before Exor announced its investment in August. Exor is the investment arm of Italy's Agnelli family, with investments in manufacturing, sport, media, fashion, healthcare and technology companies.

Persons: John Elkann, Exor, Elkann, Roy Jakobs, Philips, Italy's Agnelli, Guilio Piovaccari, Toby Sterling, Kirsten Donovan Organizations: Exor NV, Philips NV, U.S . Food, Drug Administration, Philips, Exor, Thomson Locations: TURIN, AMSTERDAM, Turin, U.S

☆ Philips raises full-year outlook as Q3 profit jumps
▼ + stars: | 2023-10-23 | by ( ) www.cnbc.com time to read: +1 min

Dutch health technology company Philips on Monday raised its full-year outlook as it beat analysts' expectations for third-quarter core profit and comparable sales. Core profit more than doubled to 457 million euros ($483.3 million), while comparable sales were up 11% at 4.5 billion euros as demand for its medical scanners, patient monitoring equipment and personal health devices increased. Despite the drop in orders, Philips said it now expected 6% to 7% comparable sales growth over 2023, with a profit margin (adjusted EBITA) of 10%-11%. Its previous outlook guided for mid-single digit sales growth with a high single digit profit margin. Analysts in a company-compiled poll had predicted adjusted July-September earnings before interest, taxes and amortisation would rise to 389 million euros from 209 million euros a year before, on 8% comparable sales growth.

Persons: Roy Jakobs, Philips Organizations: Philips, Reuters Locations: China

☆ Philips CEO: China is having a tough time, but it has 'very bright' prospects
▼ + stars: | 2023-10-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPhilips CEO: China is having a tough time, but it has 'very bright' prospectsPhilips CEO Roy Jakobs discusses the company's third-quarter results and the outlook for China.

Persons: Philips, Roy Jakobs Organizations: Philips Locations: China

☆ Royal Philips CEO: We see a strengthening of consumer demand and a upping of confidence
▼ + stars: | 2023-10-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRoyal Philips CEO: We see a strengthening of consumer demand and a upping of confidenceRoyal Philips CEO Roy Jakobs joins 'Squawk on the Street' to discuss whether Jakobs is seeing a change in global consumer demand, which markets have shown strength, and what has accounted for this strength.

Persons: Roy Jakobs Organizations: Royal Philips, Royal

☆ Philips CEO: China business, supply chain undergoing major changes
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +2 min

AMSTERDAM, Oct 19 (Reuters) - Making more products for China locally and buying chips from several suppliers are just two of the supply chain changes Dutch healthcare technology firm Philips is making due to rising trade tensions, its CEO Roy Jakobs told Reuters. "Before we were all seeking the optimal global supply chain efficiency," he said. Jakobs took the top job at Philips in 2022 amid a major recall of sleep apnea and respiratory devices. Philips' China business boomed before the pandemic, but that trend is slowing, Jakobs said. "Second, third, fourth tier suppliers in China do a lot for the whole world ...(realistically) there will be a certain continuous dependency on China".

Persons: Philips, Roy Jakobs, Jakobs, Toby Sterling, Sharon Singleton Organizations: Reuters, Philips, Thomson Locations: AMSTERDAM, China, U.S, Germany, Netherlands

☆ Philips shares fall 8% after U.S. drug regulator deals fresh blow to sleep device recall
▼ + stars: | 2023-10-06 | by ( Sam Meredith | ) www.cnbc.com time to read: +1 min

Shares of Dutch health tech company Philips tumbled to the bottom of the European benchmark on Friday, after the U.S. drug regulator deemed its handling of a major product recall inadequate. The Amsterdam-listed stock was trading more than 8% lower at 1:15 p.m. London time, paring some losses after falling by as much as 10% earlier in the session. The announcement reflects yet another blow to Philips over the recall of millions of ventilators used to treat sleep apnea, which CEO Roy Jakobs earlier this year said would be the the firm's "highest priority." The FDA said it finds additional testing is necessary and noted Philips agreed to carry out this request. The company added that it shares the same objective as the FDA and other regulators "to ensure the highest standards of patient safety and quality in the delivery of healthcare."

Persons: Roy Jakobs, Philips Organizations: Philips, U.S . Food, Drug Administration, FDA Locations: U.S, Amsterdam, London

☆ 'We are using more AI' in the healthcare industry, Philips CEO says
▼ + stars: | 2023-09-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'We are using more AI' in the healthcare industry, Philips CEO saysPhilips CEO Roy Jakobs talks about his businesses priorities and the outlook moving forward.

Persons: Roy Jakobs Organizations: Philips

AMSTERDAM, Aug 17 (Reuters) - Investment company Exor (EXOR.AS) was able to build a 15% stake in Dutch healthcare group Philips (PHG.AS) without triggering the usual disclosures thanks to derivatives deals through Goldman Sachs, regulatory filings show. Exor's investment was seen as a vote of confidence in Philips and boosted the Dutch company's shares. Filings by the Dutch Financial Market Authority AFM dated Aug. 14 but published late on Wednesday showed Goldman Sachs had taken an 12.11% stake in Philips using a derivatives structure that included 95 million call options. Sources confirmed to Reuters earlier this week that Goldman Sachs acted on behalf of Exor but could not give more details. Exor and Goldman Sachs (GS.N) declined to comment.

Persons: Goldman Sachs, Italy's Agnelli, Roy Jakobs, Exor, Allen, Overy, De Brauw, Philips, Toby Sterling, Pablo Mayo Cerqueiro, Andres Gonzalez, Valentina Za, Victoria Farr, Jane Merriman Organizations: Investment, Philips, Dutch, US Securities and Exchange, Reuters, Overy, Thomson Locations: Philips, Dutch

☆ Agnelli family's Exor buys $2.8 bln stake in Philips
▼ + stars: | 2023-08-14 | by ( Tosterling Bart H. Meijer | Bart H. Meijer | ) www.reuters.com time to read: +3 min

[1/2] Philips Healthcare headquarters is seen in Best, Netherlands August 30, 2018. The group combines two of the three sectors Exor targets in its investment strategy: healthcare and technology. While not an activist investor, Exor aims to play an active role in supporting Philips' strategy, the source said. "Exor's substantial investment underlines their confidence in Philips' transformation into a healthcare technology company and its growth and value potential," Philips Chairman Feike Sijbesma said in a statement. Philips last month reported core profit of 453 million euros and slightly upgraded financial targets for the full year.

Persons: de, Exor, Italy's Agnelli, Philips, Feike Sijbesma, John Elkann, Lifenet, Louboutin, Roy Jakobs, Valentina Za, Kim Coghill, David Goodman, Susan Fenton Organizations: Philips Healthcare, REUTERS, Philips, Philips AMSTERDAM, Exor, Institut, Ferrari, Italian soccer, Juventus, ING, U.S . Department of Justice, Thomson Locations: , Netherlands, Exor, Louboutin . New York, Italian, Milan

☆ Exor’s Philips bet looks well-timed
▼ + stars: | 2023-08-14 | by ( ) www.reuters.com time to read: +2 min

The Agnelli family’s investment company on Monday said it bought a 15% stake in the toothbrushes-to-defibrillators group for 2.6 billion euros ($2.8 billion). Philips’ shares are down some 62% since the peak in April 2021, and it now looks much cheaper than the sum of its parts. Based on peer multiples, its diagnostics business could be worth 14 times 2024 EBITDA, while its connected care unit, which helps hospitals manage patient data, might be valued at 18.5 times EBITDA. Lastly, throw in the consumer division, which makes toasters and TVs, and could fetch 12 times EBITDA. Using Refinitiv forecasts, that would imply a total enterprise value of 33 billion euros, and equity of some 24 billion euros, after taking off debt and 2.4 billion euros for legal costs estimated by Bernstein analysts.

Persons: John Elkann, Agnelli, Philips ’, EBITDA, Bernstein, Roy Jakobs, Philips, Karen Kwok, Bain, BoE, Neil Unmack, Streisand Neto Organizations: Reuters, Koninklijke Philips, U.S . Department of Justice, Philips, Twitter, FC Barcelona’s, Messi, Siemens, Thomson

SummaryCompanies Order intake down 8% in April-June periodQ2 EBITA 453 mln eur vs forecast 394 mln2023 EBITA margin now seen at upper end of provided rangeShares fall 5%July 24 (Reuters) - Health technology group Philips (PHG.AS) posted a fourth straight drop in order intake on Monday and warned that it expects global market conditions to remain highly uncertain, sending its shares down 5% from a recent 12-month high. The Amsterdam-based group, a former industrial conglomerate that now focuses on medical technology, said order intake had decreased 8% in the April-June period, the fourth quarterly fall in a row. Philips generates 15% of group sales in the People's Republic. New licensing requirements for its healthcare products in Russia were responsible for half the quarterly order decline, Jakobs said. ($1 = 0.8992 euros)Reporting by Diana Mandiá; Editing by Kirsten Donovan and David HolmesOur Standards: The Thomson Reuters Trust Principles.

Persons: Roy Jakobs, Jakobs, Philips, Abhijit Bhattacharya, Diana Mandiá, Kirsten Donovan, David Holmes Organizations: Health, Philips, European Union, ING, Thomson Locations: Amsterdam, United States, China, East, Turkey, Latin America, People's Republic, Russia, Ukraine

☆ Philips slightly raises 2023 outlook after second-quarter core profit beat
▼ + stars: | 2023-07-24 | by ( ) www.cnbc.com time to read: +2 min

(Photo by Beata Zawrzel/NurPhoto via Getty Images)Dutch health technology company Philips on Monday slightly raised its full-year targets after posting a bigger-than-expected jump in second-quarter core earnings thanks to better supply chains, a strong order book and efficiency measures. For the full year, it now expects a mid-single-digit comparable sales growth versus its previous guidance of a low-single-digit growth. Its adjusted EBITA margin is now seen at the upper end of its previously forecasted high-single-digit range. Philips, which is facing lawsuits over its recall of respiratory devices, said it had produced approximately 99% of the new replacement respiratory devices and repair kits required for the remediation of the registered affected devices. "Completing the Philips Respironics field action remains our highest priority.

Persons: Beata Zawrzel, Roy Jakobs Organizations: Philips, Getty Images, U.S . Department of Justice Locations: Warsaw, Poland, Amsterdam

☆ Philips’ convalescence has way longer to run
▼ + stars: | 2023-04-24 | by ( ) www.reuters.com time to read: +2 min

Adjusted earnings before interest, taxes and amortisation of 359 million euros beat analysts’ average estimate of 226 million euros, per Visible Alpha data. The recall of faulty breathing devices and ventilators means Philips needs to set aside another 575 million euros for lawsuits on top of over 1 billion euros last year, but that’s less than Bernstein analysts’ expectation of 2.4 billion euros. Still, probes by the U.S. Department of Justice and further claims from injured patients mean Philips may need to cough up more money. Jakobs still faces some fundamental questions: Philips’ 7% EBITA margin last year was way off rival Siemens Healthineers’ (SHLG.DE) 18%. That explains why the latter trades on 28 times its 2023 earnings, versus Philips’ 19 times.

☆ Philips makes $631 mln provision for recall litigation costs
▼ + stars: | 2023-04-24 | by ( ) www.reuters.com time to read: +1 min

Companies Koninklijke Philips NV FollowAMSTERDAM, April 24 (Reuters) - Dutch health technology company Philips (PHG.AS) on Monday said it had set aside 575 million euros ($631 million) for possible litigation costs related to its global recall of respiratory machines. Amsterdam-based Philips is grappling with the fallout of a global recall of millions of respirators used to treat sleep apnoea, announced in June 2021 over worries that foam used in the machines could become toxic. The recall has knocked off around 70% of Philips' market value over the past two years as investors fear the costs of a string of lawsuits launched by concerned patients. Philips is still working on a settlement with the U.S. Food and Drug Administration (FDA) and is subject to an investigation by the U.S. Department of Justice. Philips also reported much better-than-expected first-quarter results, as core profit jumped almost 50%, to 359 million euros, and comparable sales were 6% higher than a year before.

☆ Philips expects to reach recall settlements this year
▼ + stars: | 2023-03-30 | by ( ) www.reuters.com time to read: +1 min

Companies Koninklijke Philips NV FollowAMSTERDAM, March 30 (Reuters) - Dutch health technology company Philips (PHG.AS) expects to reach settlements this year relating to its global recall of respiratory devices, CEO Roy Jakobs said in an interview with Dutch financial daily FD published on Thursday. "I think we can at least reach a settlement on economic damages this year," Jakobs said without giving details on the expected costs. Jakobs added he "hopes and expects" to also reach a settlement with the U.S. Food and Drug Administration this year. A settlement with patients who claim the use of the recalled machines made them sick probably will take longer, he said. The economic damages claim was made by people, hospitals and health plans who say they suffered economic losses when the millions of machines were recalled.

☆ Philips to cut 13% of jobs in safety and profitability drive
▼ + stars: | 2023-01-30 | by ( Bart H. Meijer | ) www.reuters.com time to read: +3 min

The new reorganisation brings the total amount of job cuts announced by new Chief Executive Roy Jakobs in recent months to 10,000, or around 13% of Philips' current workforce. Philips shares traded up 5.5% at 0855 GMT, helped by fourth-quarter earnings which were much better than expected. "What we present today I think is a very strong plan to secure the future of Philips. Jakobs said patient safety would be put "squarely at the center" of the new organization. To improve profitability while investing in safety, innovations will be targeted at "fewer, better resourced, and more impactful projects", Jakobs said.

Search resuls for: "Roy Jakobs"

25 mentions found